SEC Comment Letter 0000000000-25-000003 to Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc.
Date: Jan. 2, 2025 · CIK: 0001583771 · Accession: 0000000000-25-000003
AI Filing Summary & Sentiment
File numbers found in text: 333-284052
Letter
January 2, 2025 John Brancaccio Interim Chief Executive Officer Hepion Pharmaceuticals, Inc. c/o Clementi Associates 919 Conestoga Road Building 3, Suite 115 Rosemont, PA 19010 Re:Hepion Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 26, 2024 File No. 333-284052 Dear John Brancaccio: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey Fessler
Show Raw Text
January 2, 2025
John Brancaccio
Interim Chief Executive Officer
Hepion Pharmaceuticals, Inc.
c/o Clementi Associates
919 Conestoga Road
Building 3, Suite 115
Rosemont, PA 19010
Re:Hepion Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 26, 2024
File No. 333-284052
Dear John Brancaccio:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey Fessler